Method for producing enteric neural precursors
AssigneesKyoto University, Takeda Pharmaceutical Company Limited
InventorsMakoto Ikeya, Yayoi Kamiya, Daisuke Kamiya, Teruyoshi Yamashita, Kazumi Take
Life of this patent
Estimating the term…
Abstract
A method for producing enteric neural precursors, comprising the steps of: (1) providing enteric neural precursors; and (2) culturing the enteric neural precursors in a medium comprising an ERBB3 agonist and/or an ERBB4 agonist is provided as a technique for allowing enteric neural precursors to proliferate by culture while maintaining their differentiation capacity into enteric nerve cells and glial cells.
Claims10
A method for producing enteric neural precursor cells, comprising the steps of:
- (1) providing SOX10-positive and PHOX2B-negative neural crest cells;
- (2) culturing the neural crest cells for differentiation in a medium comprising NRG1 and retinoic acid and/or a derivative thereof, thereby producing enteric neural precursor cells,
- wherein the derivative of retinoic acid is one or more selected form the group consisting of retinol, retinal, retinoin, isoretinoin, alitretinoin, etretinate, acitretin, tazarotene, bexarotene, and adapalene,
- wherein the medium comprises a TGFβ inhibitor and GSK3β inhibitor,
- wherein the enteric neural precursor cells are SOX10-positive and PHOX2B-positive;
- and
- (3) culturing the enteric neural precursor cells for proliferation, for a period of at least 40 days, in a medium comprising NRG1 and retinoic acid and/or derivative thereof, wherein the expanded enteric neural precursor cells are SOX10-positive and PHOX2B-positive.
An expansion culture method for enteric neural precursor cells, comprising the steps of:
- (1) providing SOX10-positive and PHOX2B-positive enteric neural precursor cells;
- and
- (2) culturing the enteric neural precursor cells for proliferation, for a period of at least 40 days, in a medium comprising NRG1 and retinoic acid and/or derivative thereof, thereby expanding enteric neural precursor cells,
- wherein the derivative of retinoic acid is one or more selected form the group consisting of retinol, retinal, retinoin, isoretinoin, alitretinoin, etretinate, acitretin, tazarotene, bexarotene, and adapalene,
- wherein the medium comprises a TGFβ inhibitor and GSK3β inhibitor,
- wherein the expanded enteric neural precursor cells are SOX10-positive and PHOX2B-positive.
Dependencies are inferred from the claim text.